DNA/RNA Extraction Kit - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The dNA/RNA extraction kit market size is expected to grow from USD 1.77 billion in 2025 to USD 1.89 billion in 2026 and is forecast to reach USD 2.68 billion by 2031 at 7.23% CAGR over 2026-2031. This report is Segmented by Product (Cell Free DNA, and More), Sample Type (Blood & Plasma, Tissue & FFPE, and More), Technology (Silica Column-Based, and More), End User (Diagnostic Centers & Clinical Labs, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global DNA/RNA Extraction Kit Market Trends and Insights

Rising Adoption of Liquid Biopsy in Oncology Diagnostics

Guardant360 CDx received FDA approval in 2024, requiring labs to validate extraction methods that preserve plasma DNA fragments under 200 base pairs. Reference centers report a 40% year-over-year growth in liquid biopsy sample volumes, necessitating upgrades to 96-well magnetic platforms that reduce handling steps. Roche’s cfDNA kit on the cobas system captures 85% of circulating tumor DNA from 2 mL of plasma, enabling the detection of minimal residual disease at an allele frequency of 0.01%. Prenatal testing also benefits, as cell-free fetal DNA replaces invasive procedures in high-income markets. Net effect raises throughput and purity requirements that manual spin columns struggle to meet.

Technological Advancements in Automated High-Throughput Extraction Platforms

Thermo Fisher’s KingFisher Apex processes 96 samples in 30 minutes with full LIMS integration, improving traceability for ISO 15189 labs. Beckman Coulter liquid handlers pair with magnetic processors to run blood, saliva, and tissue samples simultaneously, reducing the risk of cross-contamination. Tecan’s Fluent workstation combines extraction, quantification, and normalization, cutting labor costs by 60% while holding a coefficient of variation below 5%. Leasing contracts and shared-service models ease capital barriers, widening access in mid-tier hospitals. Automation thus accelerates kit conversion from low-margin manual protocols to premium cartridges.

High Capital and Reagent Costs of Automated Extraction Systems

Automated instruments cost USD 150,000-300,000, with cartridges priced at USD 200 per sample for systems like Genexus Dx, which limits viability to labs processing more than 1,000 samples per month. Manual spin columns run USD 2-5 per sample but require skilled technicians and record higher failure rates. Pay-per-use models shift capital risk to vendors but raise per-test pricing by 15%. Medicare pays USD 18 for a PCR assay, compressing margins and nudging labs toward the lowest cost extraction consumables. The resulting affordability gap stalls automation uptake in community hospitals and emerging markets.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of Precision Medicine Programs and Companion Diagnostics
• Wastewater Epidemiology Demand for Viral RNA Surveillance
• Supply Chain Vulnerabilities for Silica and Magnetic Bead Raw Materials

Segment Analysis

Cell-free DNA kits accounted for 36.43% of product revenue in 2025, reflecting their widespread adoption for liquid biopsy and prenatal testing. Total RNA kits are growing at a 9.54% CAGR as single-cell transcriptomics and spatial assays surge, requiring integrity numbers above 8.0 for downstream library preparation. Sequence-specific DNA kits remain in legacy PCR workflows, yet they are gradually ceding share to broad-capture formats aligned with next-generation sequencing. Viral RNA and microbial DNA kits remain stable after the pandemic spike, yet they continue to support wastewater and microbiome niches. Roche’s MagNA Pure 96, QIAGEN’s RNeasy Plus, and Zymo’s Quick-DNA/RNA Miniprep illustrate how vendors differentiate via automation, purity, or co-isolation advantages.

The DNA/RNA extraction kit market size for cell-free DNA kits is projected to rise at 6.4% CAGR through 2031, while total RNA solutions advance at 9.54% and are on track to close the revenue gap by 2029. Labs now standardize on dual-protocol devices to future-proof capacity against shifting assay demand, uplifting average selling prices and service revenue.

Blood and plasma generated 42.45% of the revenue in 2025, as clinicians rely on venipuncture for molecular diagnostics. Wastewater samples expand at 9.65% CAGR on the back of institutionalized epidemiological programs, elevating demand for high-volume RNA kits that handle PCR inhibitors. Tissue extraction remains critical for oncology pathology, while saliva and buccal swabs power consumer genomics and remote testing models. Stool, CSF, and niche matrices add fragmented incremental growth.

The DNA/RNA extraction kit market share for blood workflows is expected to decline to 37% by 2031 as wastewater and environmental use rise, balancing the sample mix. Vendors that optimize binding chemistries for turbid matrices stand to capture outsized gains in the expanding surveillance sector.

Complete Report Scope:

• By Product
  • Cell Free DNA
  • Sequence Specific DNA
  • Sequence Specific RNA
  • Total RNA
  • Other Products
• By Sample Type
  • Blood & Plasma
  • Tissue & FFPE
  • Saliva & Buccal Swab
  • Wastewater & Environmental Samples
  • Other Samples
• By Technology
  • Silica Column-Based
  • Magnetic Bead-Based
  • Anion-Exchange Resin
  • Reagent-Based (Phenol-Chloroform, Trizol, Etc.)
  • Automated Cartridge & Lab-On-Chip
• By End User
  • Diagnostic Centers & Clinical Labs
  • Hospitals
  • Research & Academic Institutes
  • Biotechnology & Pharmaceutical Companies
  • CROs & Others
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest Of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest Of Asia-Pacific
  • Middle East And Africa
    • GCC
    • South Africa
    • Rest Of Middle East And Africa
  • South America
    • Brazil
    • Argentina
    • Rest Of South America

Geography Analysis

North America accounted for 42.67% of the revenue in 2025, driven by high liquid biopsy volumes, well-funded precision medicine initiatives, and reimbursement that supports companion diagnostics. Europe maintains steady demand but contends with tighter budgets that shift preferences toward cost-efficient columns, despite stricter IVDR rules. Asia-Pacific is set to grow at 8.54% CAGR, propelled by the Chinese government's genomics subsidies and India’s contract-research expansion. The Middle East and Africa remain nascent, but they benefit from donor-funded infectious disease programs. South America sees moderate gains via dengue and Zika molecular surveillance.

China earmarked USD 1.2 billion in 2024 to equip provincial hospitals with automated extraction systems, cementing supplier footholds. India’s CRO industry increased its molecular testing capacity by 35% year-over-year, favoring magnetic-bead robotics that meet Good Laboratory Practice requirements. Europe’s IVDR raises compliance hurdles and nudges smaller suppliers toward mergers or exits. North American vendors pursue vertical integration to insulate raw-material supply and protect margins in a mature region. Collectively, geographic expansion rebalances growth toward emerging Asia while reinforcing regulatory-driven stickiness in developed economies.

List of Companies Covered in this Report:

• Agilent Technologies
• Bio-Rad Laboratories
• bioMérieux
• Danaher Corp. (Beckman Coulter)
• DiaSorin
• Roche
• GenScript Biotech Corp.
• Illumina
• Merck KGaA (MilliporeSigma)
• New England Biolabs
• Omega Bio-Tek Inc.
• PerkinElmer
• Promega Corp.
• QIAGEN
• Takara Bio
• Thermo Fisher Scientific
• Tecan Group
• Zymo Research Corp.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support